Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
1.
Chinese Journal of Natural Medicines (English Ed.) ; (6): 648-653, 2014.
Article in English | WPRIM | ID: wpr-812220

ABSTRACT

AIM@#The hypoglycemic and hypolipidemic effects of the methanol extract of Brassica oleracea var. capitata (MEB) was evaluated in alloxan-induced diabetic rabbits.@*METHOD@#The study was conducted on twenty-eight healthy white rabbits of either sex. All animals were equally divided into four groups. After confirmation of hyperglycemia, the animals of the treated and standard groups were administered MEB (500 mg·kg(-1)) and glibenclamide (10 mg·kg(-1)), respectively for 15 and 30 days. The animals of the normal and diabetic controls received normal saline 1 mL/day equivalent to the volume of doses given to the test and standard animals. Biochemical tests were performed at the end of dosing, i.e. the 16(th) and 31(st) days.@*RESULTS@#The MEB revealed a decrease of 106.6 mg·dL(-1) in fasting blood glucose as compared to diabetic control, which was almost comparable to glibenclamide; both of these changes were highly significant. The decrease in total cholesterol and low density lipoprotein was 94.3 and 96.5 mg·dL(-1), respectively, whereas the high-density lipoprotein was increased by 26.7 mg·dL(-1), as compared to diabetic control. All of the changes in lipid profile were statistically significant.@*CONCLUSION@#These results suggest the potential of MEB as a hypoglycemic and hypolipidemic agent.


Subject(s)
Animals , Female , Male , Rabbits , Blood Glucose , Metabolism , Brassica , Cholesterol , Blood , Diabetes Mellitus, Experimental , Blood , Drug Therapy , Hypoglycemic Agents , Pharmacology , Therapeutic Uses , Hypolipidemic Agents , Pharmacology , Therapeutic Uses , Lipoproteins , Blood , Phytotherapy , Plant Extracts , Pharmacology , Therapeutic Uses , Triglycerides , Blood
2.
Hamdard Medicus. 1998; 41 (1): 55-57
in English | IMEMR | ID: emr-48019

ABSTRACT

A new chemically synthesized piperidine derivative i.e. 1-methyl-1 [4-chloro] phenacyl-4-hydroxy piperidinium bromide was tested for analygesic activity in intact albino mice by tail flick latency in tail immersion method [Di Stasi et al., 1988]. The compound was administered orally in the doses of 50 mg/kg. Pethidine HCI 50 mg/kg was used as a reference drug. Control animals received only the vehicle. The result indicates that this compound exhibits highly significant analgesic activity


Subject(s)
Animals, Laboratory , Male , Female , Analgesics/chemical synthesis , Mice
3.
Hamdard Medicus. 1998; 41 (4): 53-55
in English | IMEMR | ID: emr-48082

ABSTRACT

Two chemically synthesized piperidinium derivatives i.e. 1-methyl-1 [4-nitro] phenacy1 4-hydroxy piperidinium bromide and 1-methyl-1 [4-bromo] phenacyl 4-hydroxy piperidinium bromide were tested for their analgesic activity in intact albino mice by tail flick latency in tail immersion method. All the compounds were administered orally in the doses of 50 mg/kg. Pethidine 50 mg/kg was used as a reference drug for comparison purpose. The results showed that both of these compounds exhibit a highly significant activity


Subject(s)
Animals, Laboratory , Piperidines/pharmacology , Mice , Analgesics
SELECTION OF CITATIONS
SEARCH DETAIL